578 related articles for article (PubMed ID: 31096928)
1. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
3. Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users.
Blankenburg M; Kovesdy CP; Fett AK; Griner RG; Gay A
BMC Nephrol; 2020 Feb; 21(1):61. PubMed ID: 32101152
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Folkerts K; Millier A; Smela B; Olewinska E; Schmedt N; Mernagh P; Kovesdy CP
J Nephrol; 2023 May; 36(4):1135-1167. PubMed ID: 36422853
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
6. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
Lo KB; Rangaswami J; Vaduganathan M
Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
[TBL] [Abstract][Full Text] [Related]
10. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Cooper LB; Lippmann SJ; Greiner MA; Sharma A; Kelly JP; Fonarow GC; Yancy CW; Heidenreich PA; Hernandez AF
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29275368
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
12. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P
JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
14. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
[TBL] [Abstract][Full Text] [Related]
15. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
16. Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Löfman I; Szummer K; Olsson H; Carrero JJ; Lund LH; Jernberg T
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29980521
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease.
Oka T; Sakaguchi Y; Hattori K; Asahina Y; Kajimoto S; Doi Y; Kaimori JY; Isaka Y
Hypertension; 2022 Mar; 79(3):679-689. PubMed ID: 35026955
[TBL] [Abstract][Full Text] [Related]
19. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry.
Guidetti F; Lund LH; Benson L; Hage C; Musella F; Stolfo D; Mol PGM; Flammer AJ; Ruschitzka F; Dahlstrom U; Rosano GMC; Braun OÖ; Savarese G
Eur J Heart Fail; 2023 Dec; 25(12):2164-2173. PubMed ID: 37795642
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease.
Baran W; Krzemińska J; Szlagor M; Wronka M; Młynarska E; Franczyk B; Rysz J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
